492 related articles for article (PubMed ID: 30244071)
41. Endogenous Na+ transport inhibitor in human hypertension: further biochemical and chemical studies.
Cloix JF; Crabos M; Grichois ML; Guicheney P; Meyer P
Klin Wochenschr; 1987; 65 Suppl 8():146-53. PubMed ID: 3037183
[TBL] [Abstract][Full Text] [Related]
42. 2-Methoxy-3,8,9-trihydroxy coumestan: a new synthetic inhibitor of Na+,K+-ATPase with an original mechanism of action.
Pôças ES; Costa PR; da Silva AJ; Noël F
Biochem Pharmacol; 2003 Dec; 66(11):2169-76. PubMed ID: 14609741
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of peripheral blood mononuclear cell proliferation by cardiac glycosides.
Gentile DA; Henry J; Katz AJ; Skoner DP
Ann Allergy Asthma Immunol; 1997 May; 78(5):466-72. PubMed ID: 9164359
[TBL] [Abstract][Full Text] [Related]
44. Characterization, quantitation, similarity evaluation and combination with Na
Bai Y; Zhu W; Xu Y; Xie Z; Akihisa T; Manosroi J; Sun H; Feng F; Liu W; Zhang J
Bioorg Chem; 2019 Jun; 87():265-275. PubMed ID: 30908969
[TBL] [Abstract][Full Text] [Related]
45. Effects of ouabain on the rotational dynamics of renal Na,K-ATPase studied by saturation-transfer EPR.
Mahaney JE; Grisham CM
Biochemistry; 1992 Feb; 31(7):2025-34. PubMed ID: 1311200
[TBL] [Abstract][Full Text] [Related]
46. Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase.
Moreno Y Banuls L; Katz A; Miklos W; Cimmino A; Tal DM; Ainbinder E; Zehl M; Urban E; Evidente A; Kopp B; Berger W; Feron O; Karlish S; Kiss R
Mol Cancer; 2013 Apr; 12():33. PubMed ID: 23621895
[TBL] [Abstract][Full Text] [Related]
47. Crosstalk between Na
Fujii T; Shimizu T; Yamamoto S; Funayama K; Fujita K; Tabuchi Y; Ikari A; Takeshima H; Sakai H
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3792-3804. PubMed ID: 30251696
[TBL] [Abstract][Full Text] [Related]
48. Ouabain-sensitive Na+,K(+)-ATPase in the plasma membrane of Leishmania mexicana.
Felibertt P; Bermúdez R; Cervino V; Dawidowicz K; Dagger F; Proverbio T; Marín R; Benaim G
Mol Biochem Parasitol; 1995 Nov; 74(2):179-87. PubMed ID: 8719159
[TBL] [Abstract][Full Text] [Related]
49. Comparative Action of Cardiotonic Steroids on Intracellular Processes in Rat Cortical Neurons.
Lopachev AV; Lopacheva OM; Nikiforova KA; Filimonov IS; Fedorova TN; Akkuratov EE
Biochemistry (Mosc); 2018 Feb; 83(2):140-151. PubMed ID: 29618300
[TBL] [Abstract][Full Text] [Related]
50. Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia.
Oselkin M; Tian D; Bergold PJ
Neurosci Lett; 2010 Apr; 473(2):67-71. PubMed ID: 19822191
[TBL] [Abstract][Full Text] [Related]
51. Retinoschisin and Cardiac Glycoside Crosstalk at the Retinal Na/K-ATPase.
Schmid V; Plössl K; Schmid C; Bernklau S; Weber BHF; Friedrich U
Invest Ophthalmol Vis Sci; 2020 May; 61(5):1. PubMed ID: 32392309
[TBL] [Abstract][Full Text] [Related]
52. Why Whip the Starving Horse When There Are Oats for the Starving Myocardium?
Fürstenwerth H
Am J Ther; 2016; 23(5):e1182-7. PubMed ID: 25259953
[TBL] [Abstract][Full Text] [Related]
53. Ouabain-like Na+,K(+)-ATPase inhibitory activity of a plasma extract in normal pregnancy and pregnancy induced hypertension.
Miyagi H; Higuchi M; Nakayama M; Moromizato H; Sakanashi M
Jpn J Pharmacol; 1991 Dec; 57(4):571-81. PubMed ID: 1666421
[TBL] [Abstract][Full Text] [Related]
54. Binding of cardiotonic steroids to Na
Kanai R; Cornelius F; Ogawa H; Motoyama K; Vilsen B; Toyoshima C
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33318128
[TBL] [Abstract][Full Text] [Related]
55. Interactions between cardiac glycosides and sodium/potassium-ATPase: three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of the enzyme versus activity inhibition.
Paula S; Tabet MR; Ball WJ
Biochemistry; 2005 Jan; 44(2):498-510. PubMed ID: 15641774
[TBL] [Abstract][Full Text] [Related]
56. Effects of digoxin and gitoxin on the enzymatic activity and kinetic parameters of Na+/K+-ATPase.
Krstić D; Krinulović K; Spasojević-Tisma V; Joksić G; Momić T; Vasić V
J Enzyme Inhib Med Chem; 2004 Oct; 19(5):409-15. PubMed ID: 15648655
[TBL] [Abstract][Full Text] [Related]
57. Comparison of low-molecular-weight plasma and urine Na-K-ATPase inhibitors/hypertensive factors.
Gonick HC; Weiler EW; Prins BA; Purdy RE
J Cardiovasc Pharmacol; 1993; 22 Suppl 2():S69-71. PubMed ID: 7508033
[TBL] [Abstract][Full Text] [Related]
58. Isolation and characterization of a specific endogenous Na+,K+-ATPase inhibitor from bovine adrenal.
Tamura M; Lam TT; Inagami T
Biochemistry; 1988 Jun; 27(12):4244-53. PubMed ID: 2844224
[TBL] [Abstract][Full Text] [Related]
59. Amino acid residues of the Na,K-ATPase involved in ouabain sensitivity do not bind the sugar moiety of cardiac glycosides.
O'Brien WJ; Wallick ET; Lingrel JB
J Biol Chem; 1993 Apr; 268(11):7707-12. PubMed ID: 8385116
[TBL] [Abstract][Full Text] [Related]
60. Role of homologous ASP334 and GLU319 in human non-gastric H,K- and Na,K-ATPases in cardiac glycoside binding.
Radkov R; Kharoubi-Hess S; Schaer D; Modyanov NN; Geering K; Horisberger JD
Biochem Biophys Res Commun; 2007 Apr; 356(1):142-6. PubMed ID: 17349614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
